Lamivudin/Zidovudin Heumann (Zidovudine, Lamivudine)

Both lamivudin and zidovudine are nucleoside reverse transcriptase inhibitors. After oral absorption, they are phosphorylated inside cells to active triphosphate forms that compete with natural nucleosides. Incorporation of these analogues into viral DNA halts chain elongation, thereby blocking HIV reverse transcription and replication.

The dosage of Lamivudin/Zidovudin is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the exact amount, frequency, and duration based on the patient’s age, weight, renal and hepatic function, and overall treatment regimen.

Safety in pregnancy and lactation has not been fully established. Clinicians should weigh the potential benefits for the mother against any possible risks to the fetus or infant. When treatment is essential, it may be continued under close medical supervision, and breastfeeding decisions should follow local guidelines.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudin/Zidovudin belongs to the NRTI class and is often compared with other fixed‑dose combinations such as tenofovir/emtricitabine. While all provide backbone therapy, the choice depends on factors like resistance profile, renal function, tolerability, and patient‑specific considerations. Lamivudin/Zidovudin has a long safety record but may have higher rates of anemia compared with some newer agents.

The product should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in humid or excessively hot environments.

Lamivudin/Zidovudin is taken orally, usually as a tablet. Patients should swallow the tablet whole with a glass of water, preferably with food to reduce gastrointestinal upset. The exact schedule—once or twice daily—depends on the prescribing clinician’s regimen.

Serious adverse events include lactic acidosis, severe hepatotoxicity, bone‑marrow suppression leading to profound anemia or neutropenia, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be instructed to seek immediate medical attention if they experience unexplained fatigue, abdominal pain, rapid breathing, or skin rash.

Lamivudin/Zidovudin is contraindicated in individuals with known hypersensitivity to lamivudin, zidovudine, or any excipients in the formulation. Caution is advised for patients with severe hepatic impairment, pre‑existing bone‑marrow disorders, or active opportunistic infections that require alternative therapy.